Keywords: GlaxoSmithKline, Lovaza, Omega-3 fatty acids, Atrial fibrilation, Fish oils

GlaxoSmithKline says Rx omega-3 fatty acids show no benefit in atrial fibrillation

Article | 16 November 2010

Print This

Findings from a new study show, compared to placebo, treatment with high-dose prescription omega-3 fatty acids did not reduce the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in